HK1201518A1 - Compositions, synthesis, and methods of using phenylcycloalkylmethylamine derivatives - Google Patents

Compositions, synthesis, and methods of using phenylcycloalkylmethylamine derivatives

Info

Publication number
HK1201518A1
HK1201518A1 HK15102110.4A HK15102110A HK1201518A1 HK 1201518 A1 HK1201518 A1 HK 1201518A1 HK 15102110 A HK15102110 A HK 15102110A HK 1201518 A1 HK1201518 A1 HK 1201518A1
Authority
HK
Hong Kong
Prior art keywords
synthesis
compositions
methods
phenylcycloalkylmethylamine derivatives
phenylcycloalkylmethylamine
Prior art date
Application number
HK15102110.4A
Other languages
English (en)
Chinese (zh)
Inventor
.巴特
.阿迪
Original Assignee
Reviva Pharmaceuticals Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Reviva Pharmaceuticals Inc filed Critical Reviva Pharmaceuticals Inc
Publication of HK1201518A1 publication Critical patent/HK1201518A1/xx

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07CACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C317/00Sulfones; Sulfoxides
    • C07C317/26Sulfones; Sulfoxides having sulfone or sulfoxide groups and nitrogen atoms, not being part of nitro or nitroso groups, bound to the same carbon skeleton
    • C07C317/28Sulfones; Sulfoxides having sulfone or sulfoxide groups and nitrogen atoms, not being part of nitro or nitroso groups, bound to the same carbon skeleton with sulfone or sulfoxide groups bound to acyclic carbon atoms of the carbon skeleton
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/24Antidepressants
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00Drugs for disorders of the metabolism
    • A61P3/04Anorexiants; Antiobesity agents
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07CACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C211/00Compounds containing amino groups bound to a carbon skeleton
    • C07C211/01Compounds containing amino groups bound to a carbon skeleton having amino groups bound to acyclic carbon atoms
    • C07C211/26Compounds containing amino groups bound to a carbon skeleton having amino groups bound to acyclic carbon atoms of an unsaturated carbon skeleton containing at least one six-membered aromatic ring
    • C07C211/27Compounds containing amino groups bound to a carbon skeleton having amino groups bound to acyclic carbon atoms of an unsaturated carbon skeleton containing at least one six-membered aromatic ring having amino groups linked to the six-membered aromatic ring by saturated carbon chains
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07CACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C211/00Compounds containing amino groups bound to a carbon skeleton
    • C07C211/01Compounds containing amino groups bound to a carbon skeleton having amino groups bound to acyclic carbon atoms
    • C07C211/26Compounds containing amino groups bound to a carbon skeleton having amino groups bound to acyclic carbon atoms of an unsaturated carbon skeleton containing at least one six-membered aromatic ring
    • C07C211/29Compounds containing amino groups bound to a carbon skeleton having amino groups bound to acyclic carbon atoms of an unsaturated carbon skeleton containing at least one six-membered aromatic ring the carbon skeleton being further substituted by halogen atoms or by nitro or nitroso groups
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07CACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C217/00Compounds containing amino and etherified hydroxy groups bound to the same carbon skeleton
    • C07C217/02Compounds containing amino and etherified hydroxy groups bound to the same carbon skeleton having etherified hydroxy groups and amino groups bound to acyclic carbon atoms of the same carbon skeleton
    • C07C217/04Compounds containing amino and etherified hydroxy groups bound to the same carbon skeleton having etherified hydroxy groups and amino groups bound to acyclic carbon atoms of the same carbon skeleton the carbon skeleton being acyclic and saturated
    • C07C217/06Compounds containing amino and etherified hydroxy groups bound to the same carbon skeleton having etherified hydroxy groups and amino groups bound to acyclic carbon atoms of the same carbon skeleton the carbon skeleton being acyclic and saturated having only one etherified hydroxy group and one amino group bound to the carbon skeleton, which is not further substituted
    • C07C217/08Compounds containing amino and etherified hydroxy groups bound to the same carbon skeleton having etherified hydroxy groups and amino groups bound to acyclic carbon atoms of the same carbon skeleton the carbon skeleton being acyclic and saturated having only one etherified hydroxy group and one amino group bound to the carbon skeleton, which is not further substituted the oxygen atom of the etherified hydroxy group being further bound to an acyclic carbon atom
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07CACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C217/00Compounds containing amino and etherified hydroxy groups bound to the same carbon skeleton
    • C07C217/54Compounds containing amino and etherified hydroxy groups bound to the same carbon skeleton having etherified hydroxy groups bound to carbon atoms of at least one six-membered aromatic ring and amino groups bound to acyclic carbon atoms or to carbon atoms of rings other than six-membered aromatic rings of the same carbon skeleton
    • C07C217/74Compounds containing amino and etherified hydroxy groups bound to the same carbon skeleton having etherified hydroxy groups bound to carbon atoms of at least one six-membered aromatic ring and amino groups bound to acyclic carbon atoms or to carbon atoms of rings other than six-membered aromatic rings of the same carbon skeleton with rings other than six-membered aromatic rings being part of the carbon skeleton
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07CACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C317/00Sulfones; Sulfoxides
    • C07C317/16Sulfones; Sulfoxides having sulfone or sulfoxide groups and singly-bound oxygen atoms bound to the same carbon skeleton
    • C07C317/18Sulfones; Sulfoxides having sulfone or sulfoxide groups and singly-bound oxygen atoms bound to the same carbon skeleton with sulfone or sulfoxide groups bound to acyclic carbon atoms of the carbon skeleton
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07CACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C317/00Sulfones; Sulfoxides
    • C07C317/44Sulfones; Sulfoxides having sulfone or sulfoxide groups and carboxyl groups bound to the same carbon skeleton
    • C07C317/48Sulfones; Sulfoxides having sulfone or sulfoxide groups and carboxyl groups bound to the same carbon skeleton the carbon skeleton being further substituted by singly-bound nitrogen atoms, not being part of nitro or nitroso groups
    • C07C317/50Sulfones; Sulfoxides having sulfone or sulfoxide groups and carboxyl groups bound to the same carbon skeleton the carbon skeleton being further substituted by singly-bound nitrogen atoms, not being part of nitro or nitroso groups at least one of the nitrogen atoms being part of any of the groups, X being a hetero atom, Y being any atom
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07CACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C323/00Thiols, sulfides, hydropolysulfides or polysulfides substituted by halogen, oxygen or nitrogen atoms, or by sulfur atoms not being part of thio groups
    • C07C323/23Thiols, sulfides, hydropolysulfides or polysulfides substituted by halogen, oxygen or nitrogen atoms, or by sulfur atoms not being part of thio groups containing thio groups and nitrogen atoms, not being part of nitro or nitroso groups, bound to the same carbon skeleton
    • C07C323/24Thiols, sulfides, hydropolysulfides or polysulfides substituted by halogen, oxygen or nitrogen atoms, or by sulfur atoms not being part of thio groups containing thio groups and nitrogen atoms, not being part of nitro or nitroso groups, bound to the same carbon skeleton having the sulfur atoms of the thio groups bound to acyclic carbon atoms of the carbon skeleton
    • C07C323/25Thiols, sulfides, hydropolysulfides or polysulfides substituted by halogen, oxygen or nitrogen atoms, or by sulfur atoms not being part of thio groups containing thio groups and nitrogen atoms, not being part of nitro or nitroso groups, bound to the same carbon skeleton having the sulfur atoms of the thio groups bound to acyclic carbon atoms of the carbon skeleton the carbon skeleton being acyclic and saturated
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07CACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C323/00Thiols, sulfides, hydropolysulfides or polysulfides substituted by halogen, oxygen or nitrogen atoms, or by sulfur atoms not being part of thio groups
    • C07C323/23Thiols, sulfides, hydropolysulfides or polysulfides substituted by halogen, oxygen or nitrogen atoms, or by sulfur atoms not being part of thio groups containing thio groups and nitrogen atoms, not being part of nitro or nitroso groups, bound to the same carbon skeleton
    • C07C323/31Thiols, sulfides, hydropolysulfides or polysulfides substituted by halogen, oxygen or nitrogen atoms, or by sulfur atoms not being part of thio groups containing thio groups and nitrogen atoms, not being part of nitro or nitroso groups, bound to the same carbon skeleton having the sulfur atom of at least one of the thio groups bound to a carbon atom of a six-membered aromatic ring of the carbon skeleton
    • C07C323/32Thiols, sulfides, hydropolysulfides or polysulfides substituted by halogen, oxygen or nitrogen atoms, or by sulfur atoms not being part of thio groups containing thio groups and nitrogen atoms, not being part of nitro or nitroso groups, bound to the same carbon skeleton having the sulfur atom of at least one of the thio groups bound to a carbon atom of a six-membered aromatic ring of the carbon skeleton having at least one of the nitrogen atoms bound to an acyclic carbon atom of the carbon skeleton
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D207/00Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D207/02Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D207/04Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
    • C07D207/08Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon radicals, substituted by hetero atoms, attached to ring carbon atoms
    • C07D207/09Radicals substituted by nitrogen atoms, not forming part of a nitro radical
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D211/00Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings
    • C07D211/04Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D211/06Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
    • C07D211/08Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms
    • C07D211/18Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms with substituted hydrocarbon radicals attached to ring carbon atoms
    • C07D211/34Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms with substituted hydrocarbon radicals attached to ring carbon atoms with hydrocarbon radicals, substituted by carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/13Amines
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07CACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C211/00Compounds containing amino groups bound to a carbon skeleton
    • C07C211/01Compounds containing amino groups bound to a carbon skeleton having amino groups bound to acyclic carbon atoms
    • C07C211/25Compounds containing amino groups bound to a carbon skeleton having amino groups bound to acyclic carbon atoms of an unsaturated carbon skeleton containing rings other than six-membered aromatic rings
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07CACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C211/00Compounds containing amino groups bound to a carbon skeleton
    • C07C211/01Compounds containing amino groups bound to a carbon skeleton having amino groups bound to acyclic carbon atoms
    • C07C211/26Compounds containing amino groups bound to a carbon skeleton having amino groups bound to acyclic carbon atoms of an unsaturated carbon skeleton containing at least one six-membered aromatic ring
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07CACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C2601/00Systems containing only non-condensed rings
    • C07C2601/02Systems containing only non-condensed rings with a three-membered ring
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07CACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C2601/00Systems containing only non-condensed rings
    • C07C2601/04Systems containing only non-condensed rings with a four-membered ring
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07CACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C2601/00Systems containing only non-condensed rings
    • C07C2601/06Systems containing only non-condensed rings with a five-membered ring
    • C07C2601/08Systems containing only non-condensed rings with a five-membered ring the ring being saturated
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07CACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C2601/00Systems containing only non-condensed rings
    • C07C2601/12Systems containing only non-condensed rings with a six-membered ring
    • C07C2601/14The ring being saturated

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Psychiatry (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Pain & Pain Management (AREA)
  • Biomedical Technology (AREA)
  • Child & Adolescent Psychology (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
HK15102110.4A 2011-12-30 2015-03-02 Compositions, synthesis, and methods of using phenylcycloalkylmethylamine derivatives HK1201518A1 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201161582201P 2011-12-30 2011-12-30
PCT/US2012/072283 WO2013102195A1 (en) 2011-12-30 2012-12-31 Compositions, synthesis, and methods of using phenylcycloalkylmethylamine derivatives

Publications (1)

Publication Number Publication Date
HK1201518A1 true HK1201518A1 (en) 2015-09-04

Family

ID=48698693

Family Applications (1)

Application Number Title Priority Date Filing Date
HK15102110.4A HK1201518A1 (en) 2011-12-30 2015-03-02 Compositions, synthesis, and methods of using phenylcycloalkylmethylamine derivatives

Country Status (21)

Country Link
US (3) US9238625B2 (cs)
EP (1) EP2797870B1 (cs)
JP (2) JP2015507635A (cs)
KR (1) KR20140110014A (cs)
CN (1) CN104039753B (cs)
AU (1) AU2012362105B2 (cs)
BR (1) BR112014016122A8 (cs)
CA (1) CA2858837C (cs)
CO (1) CO7071125A2 (cs)
ES (1) ES2726807T3 (cs)
HK (1) HK1201518A1 (cs)
IL (1) IL233083A0 (cs)
IN (1) IN2014MN01407A (cs)
MX (1) MX352874B (cs)
MY (1) MY170643A (cs)
PH (1) PH12014501313B1 (cs)
RU (1) RU2642074C2 (cs)
SG (1) SG11201403165SA (cs)
UA (1) UA114807C2 (cs)
WO (1) WO2013102195A1 (cs)
ZA (1) ZA201404711B (cs)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9238625B2 (en) 2011-12-30 2016-01-19 Reviva Pharmaceuticals, Inc. Compositions, synthesis, and methods of using phenylcycloalkylmethylamine derivatives
CA3127590A1 (en) 2019-01-28 2020-08-06 Mitochondria Emotion, Inc. Mitofusin activators and methods of use thereof
JP2022523702A (ja) 2019-01-28 2022-04-26 ミトコンドリア エモーション, インク. トランス-4-ヒドロキシシクロヘキシルフェニルアミドマイトフュージン活性化物質及びその使用方法

Family Cites Families (36)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3845770A (en) 1972-06-05 1974-11-05 Alza Corp Osmatic dispensing device for releasing beneficial agent
US3916899A (en) 1973-04-25 1975-11-04 Alza Corp Osmotic dispensing device with maximum and minimum sizes for the passageway
IE52768B1 (en) * 1981-04-06 1988-02-17 Boots Co Ltd 1-arylcyclobutylalkylamine compounds useful as therapeutic agents
ZA836848B (en) * 1982-09-30 1984-05-30 Boots Co Plc Therapeutic agents
IE56000B1 (en) * 1982-09-30 1991-03-13 Boots Co Plc 1-arylcyclobutylalkylamine compounds
US5015664A (en) 1984-01-26 1991-05-14 Oral D Orally effective ion chelators related to deferoxamine
GB8501192D0 (en) * 1985-01-17 1985-02-20 Boots Co Plc Therapeutic agents
DE3815221C2 (de) 1988-05-04 1995-06-29 Gradinger F Hermes Pharma Verwendung einer Retinol- und/oder Retinsäureester enthaltenden pharmazeutischen Zubereitung zur Inhalation zur Einwirkung auf die Schleimhäute des Tracheo-Bronchialtraktes einschließlich der Lungenalveolen
US5698155A (en) 1991-05-31 1997-12-16 Gs Technologies, Inc. Method for the manufacture of pharmaceutical cellulose capsules
ZA925185B (en) * 1991-07-18 1993-04-29 Hoffmann La Roche Dithianes.
US5596019A (en) 1995-06-07 1997-01-21 Bristol-Myers Squibb Company N-acyl-cycloalkylamine derivatives as melatonergics
GB9619757D0 (en) 1996-09-21 1996-11-06 Knoll Ag Chemical process
GB9619961D0 (en) 1996-09-25 1996-11-13 Knoll Ag Medical treatment
US6476078B2 (en) 1999-08-11 2002-11-05 Sepracor, Inc. Methods of using sibutramine metabolites in combination with a phosphodiesterase inhibitor to treat sexual dysfunction
US6323242B1 (en) 1998-12-02 2001-11-27 Peter Sterling Mueller Treatment of disorders secondary to organic impairments
GB9914742D0 (en) 1999-06-24 1999-08-25 Knoll Ag Therapeutic agents
GB9914744D0 (en) 1999-06-24 1999-08-25 Knoll Ag Therapeutic agents
US6399826B1 (en) 1999-08-11 2002-06-04 Sepracor Inc. Salts of sibutramine metabolites, methods of making sibutramine metabolites and intermediates useful in the same, and methods of treating pain
WO2002036540A2 (en) 2000-11-02 2002-05-10 Torrent Pharmaceuticals Ltd PROCESS FOR PREPARATION OF β-PHENETHYLAMINE DERIVATIVE
ATE353900T1 (de) 2001-02-24 2007-03-15 Boehringer Ingelheim Pharma Xanthinderivate, deren herstellung und deren verwendung als arzneimittel
WO2002083631A1 (en) 2001-04-13 2002-10-24 Sepracor Inc. Methods of preparing didesmethylsibutramine and other sibutramine derivatives
GB0230134D0 (en) 2002-12-24 2003-01-29 Amedis Pharm Ltd Compounds and their use
WO2004096202A1 (en) 2003-04-28 2004-11-11 Cipla Limited Pharmaceutical formulation comprising anti-obesity agent and acidulant
RS20110578A3 (en) 2003-10-14 2016-02-29 F. Hoffmann-La Roche Ltd MACROCYCLIC CARBOXYLIC ACIDS AND ACYLSULPHONAMIDES AS HCV REPLICATION INHIBITORS
EP1595873A1 (de) * 2004-05-13 2005-11-16 Boehringer Ingelheim Pharma GmbH & Co.KG Substituierte Cycloalkylderivate zur Behandlung von Atemswegerkrankungen
CA2617546C (en) * 2005-08-03 2014-07-15 Boehringer Ingelheim International Gmbh Use of flibanserin in the treatment of obesity
RU2430913C2 (ru) * 2006-01-06 2011-10-10 Сепракор Инк. Циклоалкиламины в качестве ингибиторов повторного поглощения моноамина
JP2007254409A (ja) * 2006-03-24 2007-10-04 Taisho Pharmaceut Co Ltd イミダゾリジノン誘導体
KR101441146B1 (ko) 2006-04-28 2014-09-17 시오노기세야쿠 가부시키가이샤 Npy y5 수용체 길항 작용을 갖는 아민 유도체
JP2010503709A (ja) 2006-09-15 2010-02-04 レビバ ファーマシューティカルズ,インコーポレーテッド シクロアルキルメチルアミンの合成、使用方法および組成物
SA08290668B1 (ar) * 2007-10-25 2012-02-12 شيونوجي آند كو.، ليمتد مشتقات أمين لها نشاط مضاد لمستقبل npy y5 واستخداماتها
WO2009057079A2 (en) 2007-11-01 2009-05-07 Actelion Pharmaceuticals Ltd Novel pyrimidine derivatives
CA2759264A1 (en) * 2009-04-21 2010-10-28 Astellas Pharma Inc. Diacylethylenediamine compound
US8227618B2 (en) * 2009-04-23 2012-07-24 Shionogi & Co., Ltd. Amine-derivatives having NPY Y5 receptor antagonistic activity and the uses thereof
WO2012003501A2 (en) 2010-07-02 2012-01-05 Reviva Pharmaceuticals, Inc. Compositions, synthesis, and methods of using cycloalkylmethylamine derivatives
US9238625B2 (en) 2011-12-30 2016-01-19 Reviva Pharmaceuticals, Inc. Compositions, synthesis, and methods of using phenylcycloalkylmethylamine derivatives

Also Published As

Publication number Publication date
MX352874B (es) 2017-12-13
AU2012362105A1 (en) 2014-07-31
US9238625B2 (en) 2016-01-19
RU2642074C2 (ru) 2018-01-24
BR112014016122A2 (pt) 2017-06-13
PH12014501313A1 (en) 2014-09-15
ZA201404711B (en) 2015-08-26
JP2018138566A (ja) 2018-09-06
UA114807C2 (uk) 2017-08-10
US20180127362A1 (en) 2018-05-10
CA2858837C (en) 2022-08-30
CO7071125A2 (es) 2014-09-30
ES2726807T3 (es) 2019-10-09
EP2797870A4 (en) 2015-05-27
KR20140110014A (ko) 2014-09-16
EP2797870B1 (en) 2019-02-20
CN104039753A (zh) 2014-09-10
PH12014501313B1 (en) 2014-09-15
SG11201403165SA (en) 2014-08-28
US20140024679A1 (en) 2014-01-23
EP2797870A1 (en) 2014-11-05
AU2012362105B2 (en) 2017-09-07
IL233083A0 (en) 2014-08-03
NZ627327A (en) 2016-07-29
RU2014129416A (ru) 2016-02-20
US9695116B2 (en) 2017-07-04
US20160115121A1 (en) 2016-04-28
IN2014MN01407A (cs) 2015-07-03
BR112014016122A8 (pt) 2017-07-04
CN104039753B (zh) 2016-09-14
WO2013102195A8 (en) 2014-02-13
US10035761B2 (en) 2018-07-31
CA2858837A1 (en) 2013-07-04
MX2014007879A (es) 2014-09-22
MY170643A (en) 2019-08-22
JP2015507635A (ja) 2015-03-12
WO2013102195A1 (en) 2013-07-04

Similar Documents

Publication Publication Date Title
HK1244183A1 (zh) Ivacaftor的氘化衍生物
IL237581B (en) Derivatives of 6-oxo-pyrazinopyrrolopyrimidines
HK1199255A1 (en) Indazole compounds, compositions and methods of use
HK1199726A1 (en) Kynurenine-3-monooxygenase inhibitors, pharmaceutical compositions, and methods of use thereof -3-
HUE047354T2 (hu) Ivacaftor deuterizált származékai
EP2675471A4 (en) HSA-RELATED COMPOSITIONS AND USE PROCESSES
IL222291A0 (en) Compositions and methods of synthesis of pyridinoylpiperidine
HK1199705A1 (en) Kynurenine-3-monooxygenase inhibitors, pharmaceutical compositions, and methods of use thereof -3-
EP2582664A4 (en) PHENYL THIOACETATE COMPOUNDS AND COMPOSITIONS AND METHOD FOR THEIR USE
IL228604A0 (en) Synthesis of 5-azacytidine
EP2721045A4 (en) COMPOSITIONS, METHODS OF SYNTHESIS AND USE OF TARGETED AGENTS ON CARBOHYDRIDES
HK1200366A1 (en) Pharmaceutical compositions and methods of use of 4-pregenen-11ss-17- 21-triol-3,20-dione derivatives 4--11-17-21--320-
EP2691396A4 (en) ENOPEPTINES, USES THEREOF, AND METHODS OF SYNTHESIZING THE SAME
HK1207824A1 (en) Polymorph compositions, methods of making, and uses thereof
HK1198365A1 (en) Imidazopyridine compounds, compositions and methods of use
HK1199793A1 (en) Opsin-binding ligands, compositions and methods of use
EP2738159A4 (en) MERCAPTO-BENZOPHENONE COMPOUNDS, COMPOSITIONS AND METHODS OF PREPARATION THEREOF
PL2694532T3 (pl) Pochodne aureobasidin i sposoby syntezy
HK1201518A1 (en) Compositions, synthesis, and methods of using phenylcycloalkylmethylamine derivatives
HK1201414A1 (en) Opsin-binding ligands, compositions and methods of use
EP2804607A4 (en) SYNTHESIS OF RALTEGRAVIR
EP2785346A4 (en) OPSINBINDING LIGANDS, COMPOSITIONS THEREOF, AND METHOD OF USE THEREOF
EP2785178A4 (en) OPSINBINDING LIGANDS, COMPOSITIONS THEREOF, AND METHOD OF USE THEREOF
TH1401003816A (th) องค์ประกอบ, การสังเคราะห์, และ วิธีการของการใช้อนุพันธ์ฟีนิลไซโคลอัลคิลเมทธิลเอมีน